BiotechTube

Sotagliflozin + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obstructive Cardiomyopathy, Hypertrophic

Conditions

Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

Trial Timeline

Sep 24, 2024 → Aug 1, 2026

NCT ID
NCT06481891

About Sotagliflozin + Placebo

Sotagliflozin + Placebo is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Obstructive Cardiomyopathy, Hypertrophic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06481891. Target conditions include Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy.

What happened to similar drugs?

20 of 20 similar drugs in Obstructive Cardiomyopathy, Hypertrophic were approved

Approved (20) Terminated (2) Active (0)
✅lysozyme 90 mg + PlaceboEisaiApproved
✅Eszopiclone + Placebo controlSumitomo PharmaApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Lunesta + Placebo controlSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06435156Phase 2Recruiting
NCT06481891Phase 3Recruiting

Competing Products

20 competing products in Obstructive Cardiomyopathy, Hypertrophic

See all competitors
ProductCompanyStageHype Score
Daridorexant + PlaceboIdorsiaPhase 1
23
Mavacamten + PlaceboLianBioPhase 3
30
CT-G20 + PlaceboCelltrionPhase 1
21
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mgEisaiPhase 1
29
lysozyme 90 mg + PlaceboEisaiApproved
43
Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mgEisaiPhase 1
29
Eloralintide + PlaceboEli LillyPhase 3
47
Tirzepatide + PlaceboEli LillyPhase 3
40
Arformoterol tartrate inhalation solution + Arformoterol 25 ųg BID + Formoterol 12 ųg BID + PlaceboSumitomo PharmaPhase 3
40
arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + Salmeterol + PlaceboSumitomo PharmaPhase 3
40
arformoterol + salmeterolSumitomo PharmaPre-clinical
26
Eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Arformoterol + PlaceboSumitomo PharmaPhase 3
40
Eszopiclone + Placebo controlSumitomo PharmaApproved
43
Eszopiclone + PlaceboSumitomo PharmaPhase 1
29
Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
43
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
35
Lunesta + Placebo controlSumitomo PharmaApproved
43
Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
39